Category: biotech

.Frazier Life Sciences has actually sourced a better $630 thousand for its own fund focused on little and also mid-cap biotechs.The most up to date

.After antibody-drug conjugate (ADC) expert Seagen was sold to Pfizer in 2014 for a monstrous $43 billion, former CEO David Epstein stated he was seeking

.Amidst the hereditary medicines arms ethnicity, Flagship Pioneering is actually revealing a brand-new provider to aid biotechs adjust the preciseness of their therapies.The venture development

.Allow’s study a discussion along with Ayla Ellison, Brutal Biotech Editor-in-Chief as well as Michelle Benz as they go over the highlights and exhilaration neighboring

.After F2G’s 1st attempt to receive a brand-new course of antifungal to market was wrecked due to the FDA, the U.K.-based biotech has secured $one

.The FDA has actually executed a predisposed hold on a period 3 non-small tissue lung cancer practice run through BioNTech and OncoC4 after observing differing

.After dismissing the selection meeting for Applied Therapeutics’ metabolic ailment medication govorestat, the FDA has actually now determined that an intended advising committee appointment will

.For Lykos Therapies and the provider’s prospective MDMA-assisted therapy for trauma (POST-TRAUMATIC STRESS DISORDER), the smash hits only keep coming..Previously this month, Lykos was actually

.The FDA has put Kezar Life Sciences’ lupus trial on hold after the biotech flagged 4 deaths throughout the period 2b research study.Kezar had actually

.Five months after approving Utility Rehabs’ Pivya as the 1st brand-new procedure for uncomplicated urinary system diseases (uUTIs) in more than 20 years, the FDA